uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

BMC Cancer

Table 3 Median concentrations in plasma of uPA (pg/mL), PGE₂ (ng/mL) and celecoxib (ng/mL) based on celecoxib dose and menopausal status¹

Dose	N	Baseline	After Tx	Δ	P Value	Celecoxib
200 mg bid ²
uPA
Overall	17	941.4	955.0	-20.7	0.85	233.7
Premen	4	886.9	1031.8	36.0	0.62	195.3
Postmen	13	994.0	945.6	-20.7	0.64	233.7
PGE ₂
Overall	17	0.209	0.206	0.005	0.96	233.7
Premen	4	0.244	0.221	0.100	0.99	0
Postmen	13	0.204	0.195	0.005	0.84	233.7
400 mg bid ²
uPA
Overall	25	908.3	910.7	17.5	0.8	696.0
Premen	11	864.9	821.0	17.5	0.8	227.3
Postmen	14	1036.1	992.4	7.9	0.7	1024.9
PGE ₂
Overall	25	0.280	0.203	-0.009	0.93	696.0
Premen	11	0.375	0.366	-0.001	0.77	227.2
Postmen	14	0.280	0.175	-0.023	0.90	1025.0

1: N: sample size; NAF: nipple aspirate fluid. Units reflect pg uPA/mL plasma volume. Δ uPA reflects the median of the change measured in each subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after treatment.
2: bid: twice daily; premen: premenopausal; postmen: postmenopausal.

ISSN: 1471-2407